Improving Drug Safety: Active Surveillance Systems Should be Paramount

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.23, Iss.3, 2009-06, pp. : 127-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Defining `Surveillance' in Drug Safety

By Aronson Jeffrey K. Hauben Manfred Bate Andrew

Drug Safety, Vol. 35, Iss. 5, 2012-05 ,pp. : 347-357

Adis International

Access to resources Recommend Favorite

Postmarketing Drug Safety Surveillance: An Overview of Regulatory Issues

By Wu J.H.

Pharmaceutical Development and Regulation, Vol. 1, Iss. 4, 2003-01 ,pp. : 231-244

Adis International

Access to resources Recommend Favorite

Trains, conkers and audit: safety can never be paramount

Clinical Medicine, Vol. 1, Iss. 2, 2001-03 ,pp. : 157-158

Royal College Of Physicians

Access to resources Recommend Favorite

A Pharmacoepidemiological Network Model for Drug Safety Surveillance: Statins and Rhabdomyolysis

By Reis Ben Y.

Drug Safety, Vol. 35, Iss. 5, 2012-05 ,pp. : 395-406

Adis International

Access to resources Recommend Favorite

Health-insurance-claims databases may be able to be used for drug-safety surveillance

Reactions Weekly, Vol. 1, Iss. 1287, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite